Compare Regeneron Pharmaceuticals Inc (REGN) vs Upstart Holdings Inc (UPST) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Upstart Holdings (UPST) trades at $26.98, down 3.81% on the day, reflecting bearish technical momentum and recent earnings misses. The stock shows oversold conditions with an RSI of 18.98, while fundamentals indicate a turnaround with 2025 net income of $53.60M on $1.02B revenue, marking its first annual profit. Analyst sentiment is mixed with a 45.46% buy rating and $47.20 consensus target, but insider selling and weak cash flow from operations pose concerns.

The outlook hinges on execution in personal loan growth and AI lending efficiency, but risks include high debt-to-asset ratio of 61.48% and macroeconomic sensitivity. Near-term resistance at $28 challenges upside, while support at $26 may stabilize declines if earnings improve in Q3 2026.